Abstract
Camrelizumab combined with neoadjuvant docetaxel, oxaliplatin, and S1 as induction therapy for locally advanced esophageal squamous cell cancer: a real-world single-center cohort study
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have